Ofatumumab Application to FDA for the Treatment of Advanced Stage Blood Cancer 

The Use of Erythropoiesis Stimulating Agents in Cancer and Related Neoplastic Conditions
The Centers for Medicare and Medicaid Services is seeking public comment on their proposed determination that there is sufficient evidence to conclude that erythropoiesis stimulating agent (ESA) treatment is not reasonable and necessary for beneficiaries with certain clinical conditions, either because of a deleterious effect of the ESA on their underlying disease or because the underlying disease increases their risk of adverse effects related to ESA use. Click here to read more of CMS proposed decision.

ONS Response to CMS Proposed Decision

US Food and Drug Administration Health Advisory

Commentary on the CMS Proposed Ruling from Other Organizations